Health and social care organisations in Derbyshire have been working closely together for some time, to improve care and services for people and make them as efficient and effective as possible.
On Wednesday 7 April, the Medicines and Healthcare products Regulatory Agency (MHRA) issued new advice, concluding a possible link between COVID-19 Vaccine AstraZeneca and extremely rare, unlikely to occur blood clots. They also said that the benefits of vaccination continue to outweigh any risks but the MHRA advises careful consideration be given to people who are at higher risk of specific types of blood clots because of their medical condition.
The Joint Committee on Vaccination and Immunisation (JCVI) has advised:
You can read the JCVI statement here.
What does the European Medicines Agency say?
On Wednesday 7 April, European Medicines Agency’s safety committee (PRAC) concluded that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca) but confirmed that the overall benefit-risk remains positive.
Website built by Frank